DMAC (STOCKS)
DiaMedica Therapeutics Inc. Common Stock
$8.300000
-0.060000 (-0.72%)
Prev close: $8.360000
Company Information
- Exchange
- XNAS
- Sector
- Health Technology
- Industry
- Biotechnology
- CEO
- Rick John Pauls
- Asset Type
- stocks
- Website
- Visit
Fundamentals
- Market Cap
- $443.39M
- Employees
- 28
- P/E (TTM)
- -11.65
- P/B (TTM)
- 8.43
- Dividend Yield
- —
Technical Indicators
- SMA 10
- —
- SMA 20
- —
- SMA 50
- —
- EMA 9
- —
- EMA 21
- —
- RSI
- —
- MACD State
- —
Analyst Recommendations
2
Strong Buy
8
Buy
1
Hold
0
Sell
Recent News
No recent news found for this ticker.
Earnings Surprises
| Period | Actual | Estimate | Surprise | Surprise % |
|---|---|---|---|---|
|
Sep 2025 (Q3)
|
$-0.17 | $-0.16 | -0.0068 | -4.17% |
|
Jun 2025 (Q2)
|
$-0.18 | $-0.19 | +0.0138 | +7.12% |
|
Mar 2025 (Q1)
|
$-0.18 | $-0.18 | +0.0036 | +1.96% |
|
Dec 2024 (Q4)
|
$-0.18 | $-0.18 | -0.0040 | -2.27% |
Financial Statements
| Nonoperating Income/Loss | $1.70M |
| Research and Development | $24.39M |
| Operating Income/Loss | -$33.60M |
| Income/Loss From Continuing Operations After Tax | -$31.93M |
| Income/Loss From Continuing Operations Before Tax | -$31.90M |
| Income Tax Expense/Benefit | $27.00K |
| Net Income/Loss | -$31.93M |
| Net Income/Loss Attributable To Noncontrolling Interest | $0.00 |
| Net Income/Loss Attributable To Parent | -$31.93M |
| Net Income/Loss Available To Common Stockholders, Basic | -$31.93M |
| Participating Securities, Distributed And Undistributed Earnings/Loss, Basic | $0.00 |
| Preferred Stock Dividends And Other Adjustments | $0.00 |
| Basic Earnings Per Share | -$0.71 |
| Basic Average Shares | 93,331,714 |
| Assets | $57.05M |
| Current Assets | $56.22M |
| Cash | $55.30M |
| Other Current Assets | $923.00K |
| Noncurrent Assets | $824.00K |
| Fixed Assets | $150.00K |
| Other Non-current Assets | $674.00K |
| Liabilities | $5.43M |
| Current Liabilities | $5.27M |
| Accounts Payable | $1.92M |
| Wages | $920.00K |
| Other Current Liabilities | $2.43M |
| Noncurrent Liabilities | $157.00K |
| Equity | $51.62M |
| Equity Attributable To Noncontrolling Interest | $0.00 |
| Equity Attributable To Parent | $51.62M |
| Liabilities And Equity | $57.05M |
| Net Cash Flow From Operating Activities | -$27.73M |
| Net Cash Flow From Operating Activities, Continuing | -$27.73M |
| Net Cash Flow From Investing Activities | -$4.98M |
| Net Cash Flow From Investing Activities, Continuing | -$4.98M |
| Net Cash Flow From Financing Activities | $31.91M |
| Net Cash Flow From Financing Activities, Continuing | $31.91M |
| Net Cash Flow | -$808.00K |
| Net Cash Flow, Continuing | -$808.00K |
| Comprehensive Income/Loss | -$31.92M |
| Comprehensive Income/Loss Attributable To Noncontrolling Interest | $0.00 |
| Comprehensive Income/Loss Attributable To Parent | -$31.96M |
| Other Comprehensive Income/Loss | -$16.51M |